Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Monday, October 12, 2026

Back to today

From X

@StableBread

Fajasy on X

BWX Technologies’ $BWXT commercial segment grew Q2 2026 revenue 72% to $302.5M, while its government segment grew just 2% to $601.3M. $BWXT reported Q2 2026 on August 3, and CEO Rex Geveden called it “another strong quarter characterized by excellent execution across the company”: → Revenue: $901.6M, up 18% y/y (9% organic). → Adjusted EBITDA: $155.5M, up 7%, a 17.2% margin vs. 19.1%. The government segment fell 5% to $126.5M, but grew 22.1% excluding a $29.4M one-time contract gain in Q2 2025, while the commercial segment more than doubled to $36.1M. → EPS: $0.97 GAAP (+14%) and $1.07 non-GAAP (+5%). → FCF: $115.0M, down 9%, as capex rose 27% to $41.4M. → Backlog: $8.4B, up 40% y/y, including $2.26B of government contracts not yet funded by Congress. Q2 bookings were $648.9M vs. $1,640.5M a year earlier, but over the past 12 months, new orders still ran 1.7x revenue. The 2026 guide now calls for $3.8B of revenue, $662-672M of adjusted EBITDA (a 17.5% margin), $4.70-4.80 of non-GAAP EPS, and $345-360M of FCF. In August, $BWXT also changed its guidance for both segments: 1) Government Operations: Lower revenue growth (high single digits, down from low teens) but a higher margin (20.5%, up from 19% at the start of 2026). CFO Mike Fitzgerald said on the Q2 call that high-purity depleted uranium (HPDU) costs are coming in under budget. Most of the segment’s contracts pay $BWXT its costs plus a fee, and the fee goes up when $BWXT spends less than the target cost, so lower HPDU costs mean less revenue but more profit. 2) Commercial Operations: Higher revenue growth (45%, up from 30%), with Precision Components Group (PCG), acquired July 1, adding slightly more than half of the increase, but a lower margin (13%, down from 14%) as $BWXT spends on U.S. capacity and new hires.

Investor Letters

All letters

“Is Ralph Lauren Still Relevant?”

Ralph Lauren’s 2017 CEO change put Patrice Louvet in charge of reversing nine quarters of same-store sales declines and restoring the…

RL $22B
TSOH Investment Research 1 click

A temporary glitch?

Coupang’s November 2025 cybersecurity breach tests whether a selloff is temporary despite its 28% Korean e-commerce share, 14 million-plus…

CPNG $27B
Asian Century Stocks 9 clicks

TSOH Weekly Roundup (10/09/2026)

Paramount Skydance’s debt-heavy Warner Bros. Discovery acquisition, streaming bundle pricing and alcohol-industry diversification anchor…

WBD $78B
TSOH Investment Research
MOH · long

Molina Healthcare

Molina Healthcare faces unprecedented Medicaid managed-care cost inflation and margin compression after its shares declined since October…

MOH $11B
Value Investors Club

Research Roundup Vol. XLIX

Research Roundup Vol. XLIX covers 3.4% inflation, AI compute demand, data center buildouts, and Q2 reports from Rocket Lab, CoreWeave,…

RKLB $35BCRWV $43B
Monte Independent Investment Research

Boston Scientific (BSX): New Position

Boston Scientific’s Farapulse competition and weaker Watchman demand have slowed growth, prompting a $2 billion buyback, restructuring and…

BSX $61B
Aurelion Research 1 click

Revisiting Veeva #2

Veeva plans Falcon agents for pharmacovigilance, clinical-trial documents and regulatory writing, targeting multibillion-dollar…

VEEV $48B
Lewistown Capital

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 49 of 228

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

88 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.